Post-transplantation lymphoproliferative disorders: Advances in diagnosis, prevention and management in children

Progress in Pediatric Cardiology

Volumn 11, Issue 2, 2000, Pages 145-157

  Webber, Steven A ^a   Green, Michael ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Epstein Barr virus; Immunosuppression; Infancy and childhood; Lymphoproliferative disorders; Post transplantation complications

Indexed keywords

ADOLESCENT; CHILD; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 0034212404     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(00)00044-8     Document Type: Article

References (39)

1. Starzl T.E. Discussion of Murry JE, Wilson RE, Tilney NL et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg. 168:1968;416.
2. Briggs J.D., Hamilton D.N.H., Macsween R.N.M. et al. Infectious mononucleosis, herpes simplex infection and diffuse lymphoma in a renal transplant patient. Transplantation. 25:1978;227.
3. Ho M. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc. 27:1995;38-40.
4. Chadburn A., Cesarman E., Knowles D.M. Molecular pathology of posttransplant lymphoproliferative disorders. Sem Diagn Pathol. 14:1997;15-26.
5. Webber S.A. Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation? [Editorial]. Pediatr Transplant. 3:1999;95-99.
6. Zangwill S.D., Hsu D.T., Kichuk M.R. et al. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transplant. 17:1998;1161-1166.
7. Finn L., Reyes J., Bueno J., Yunis E. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol. 22:1998;299-309.
8. Cen H., Breinig M.C., Atchison R.W., Ho M., McKnight J.L.C. Epstein-Barr virus transmission via the donor organ in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3 and IR4. J Virol. 65:1991;976-980.
9. Haque T., Thomas J.A., Falk K.I. et al. Transmission of Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol. 77:1996;1169-1172.
10. Swinnen L.J., Costanzo-Nordin M.R., Fisher S.G. et al. Increased incidence of lymphoproliferative disorders after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients. New Engl J Med. 323:1990;1723-1728.
11. Newell K.A., Alonso E.M., Whitington P.F. et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Transplantation. 62:1996;370-375.
12. Cox K.L., Lawrence-Miyasaki L.S., Garcia-Kennedy R. et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disease in young children on FK506 after liver transplantation. Transplantation. 59:1995;524-529.
13. Ciancio G., Siquijor A.P., Burke G.W. et al. Post-transplant lymphoproliferative disease in kidney transplant recipients in the new immunosuppressive era. Clin Transplant. 11:1997;243-249.
14. Webber S.A. Fifteen years of pediatric heart transplantation at the University of Pittsburgh: lessons learned and future prospects. Pediatr Transplant. 1:1997;8-21.
15. Bernstein D., Baum D., Berry G. et al. Neoplastic disorders after pediatric heart transplantation. Circulation. 88(part 2):1993;230-237.
16. Riddler S.A., Breinig M.C., McKnight J.L.C. Increased levels of circulating Epstein-Barr virus-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood. 84:1994;972-984.
17. Harwood J.S., Gould F.K., McMaster A. et al. Significance of EBV status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation. Pediatr Transplant. 3:1999;100-103.
18. Boyle G.J., Michaels M.G., Webber S.A. et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr. 131:1997;309-313.
19. Sweet S.C., Spray T.L., Huddleston C.B. et al. Pediatric lung transplantation at St. Louis Children's Hospital, 1990-1995. Am J Resp Crit Care Med. 155:1997;1027-1035.
20. Eisen H.J., Hicks D., Kant J.A. et al. Diagnosis of posttransplant lymphoproliferative disorder by endomyocardial biopsy in a cardiac allograft recipient. J Heart Lung Transplant. 13:1994;241-245.
21. Green M., Reyes J., Webber S., Michaels M.G., Rowe D. The role of viral load in the diagnosis, management and possible prevention of EBV-associated post-transplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant. 4:1999;292-296.
22. Rowe D.T., Qu L., Reyes J. et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant recipients with lymphoproliferative disorders. J Clin Microbiol. 35:1997;1612-1615.
23. Harris N.L., Ferry J.A., Swerdlow S.H. Post-transplant lymphoproliferative disorders: summary of Society for Hematopathology work shop. Sem Diagn Pathol. 14:1997;8-14.
24. Nalesnik M.A., Starzl T.E. Epstein-Barr virus, infectious mononucleosis, and post-transplant lymphoproliferative disorders. Transplant Sci. 4:1994;61-79.
25. Knowles D.M., Cesarman E., Chadburn A. et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplant lymphoproliferative disorders. Blood. 85:1995;552-565.
26. Lee E.S., Locker J., Nalesnik M. et al. The association of Epstein-Barr virus with smooth muscle tumors occurring after organ transplantation. New Engl J Med. 332:1995;19-25.
27. Epstein M.A., Morgan A.J., Finerty S. et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature. 318:1985;287-289.
28. Green M., Reyes J., Rowe D. New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant. 3:1998;143-147.
29. Abedi M.R., Linde A., Christensson B., Mackett M., Hammarstrom L., Smith C. Preventive effect of IgG from EBV-seropositive donors on the development of human lymphoproliferative disease in SCID mice. Int J Cancer. 71:1997;624-629.
30. Green M., Michaels M.G., Webber S.A., Rowe D., Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients. Pediatr Transplant. 3:1999;271-281.
31. Starzl T.E., Nalesnik M.A., Porter K.A. et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1:1984;583-587.
32. Shapiro R.S., Chauvenet A., McGuire W. et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. New Engl J Med. 318:1988;1334.
33. Ippoliti, Martinelli L, Loernzutti F et al. Post-transplant lymphoproliferative disease after heart transplantation on Sandimmune therapy: treatment with interferon-alpha 2b and intravenous immunoglobulin. Trans Proc 1995;26:2660-2661.
34. Fisher A., Blanche S., Le Bidois J. et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. New Engl J Med. 324:1991;1451-1456.
35. Senderowicz A.M., Vitetta E., Headlee D. et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 126:1997;882-885.
36. Nalesnik M.A., Rao A.S., Furukawa H. et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus positive and negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation. 63:1997;1200-1205.
37. Rooney C.M., Smith C.A., Ng C.Y.C. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus related lymphoproliferation. Lancet. 345:1995;9-13.
38. Emanuel D.J., Lucas K.G., Mallory G.B. et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation. 63:1997;1691-1694.
39. Swinnen L.J., Mullen G.M., Carr T.J., Costanzo M.R., Fisher R.I. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 86:1995;3333-3340.